Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Saved in:
| Title: | Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. |
|---|---|
| Authors: | Sivakumaran, T.1 (AUTHOR) tharani.sivakumaran@petermac.org, Mileshkin, L.1,2 (AUTHOR), Grant, P.3 (AUTHOR), Na, L.1 (AUTHOR), DeFazio, A.4,5 (AUTHOR), Friedlander, M.6 (AUTHOR), Obermair, A.7 (AUTHOR), Webb, P.M.8 (AUTHOR), Au-Yeung, G.1,2 (AUTHOR) |
| Source: | Gynecologic Oncology. Jul2020, Vol. 158 Issue 1, p47-53. 7p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2020.04.706 |
